AGM Information • Apr 22, 2020
AGM Information
Open in ViewerOpens in native device viewer
Liege, Belgium, 22 April 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health today announces the publication of its 2019 Annual Report and the invitation to its Ordinary and Extraordinary General Securities holders.
The Annual Report which outlines Mithra's achievements in 2019 includes the following information:
The Annual Report is available in English and French and can be read (or downloaded in PDF) on the website investors.mithra.com. In case of interpretation differences, the French version will prevail.
François Fornieri, CEO Mithra Women's Health, commented: "2019 marked our 20th anniversary and was exceptional in more ways than one. We recorded a strong turnover increase, achieved key milestones in both clinical development and international growth, and a CDMO that successfully moved into commercial production. In 2020, despite this unprecedented situation caused by Covid-19, our teams are determined to do everything possible to meet our ambitious challenges."
Mithra is pleased to invite its securities holders to its Ordinary and Extraordinary General Shareholder's meeting that will be held on Friday May 22 2020 at 2:00 PM (CEST).
The notice for the General Shareholder's Meeting including a description of the formalities to participate in the Meeting is available on the website investors.mithra.com.
Further to the protection measures adopted by the Belgian Government prohibiting the physical presence of the shareholders during a shareholders' meeting, the Company has decided to impose to the shareholders to vote exclusively by written proxy, as prescribed by the Belgian Royal Decree n°4 dated April 9, 2020. On that basis, shareholders who wish to vote at that shareholders' meeting must provide the Company with the proxy form described below.
The right to participate in the General Shareholder's Meeting and to vote is subject to the prior accounting registration of the shares under the shareholder's name on 8 May 2020 at midnight (Belgian time) (the "Record Date"), either by way of registration on the company's share register, or either by way of registration in book entry form in an account held with a settlement institution or a certified account holder, without taking into account the number of shares held by the shareholder at the day of the General Meeting. Only persons who are shareholders on the Record Date are entitled to vote at the general meeting.
A certification is delivered to the shareholder by the settlement institution or certified account holder which certifies the number of dematerialized shares registered in its accounts under the name of the shareholder on the Record Date, for which the shareholder has expressed its intention to participate in the general meeting.
The shareholder indicates his willingness to participate in the General Meeting by 16 May 2020 at the latest. This must be done by email to [email protected], or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège.
The directors answer questions that are asked by the shareholders, in writing before the meeting, concerning their report or the agenda, in accordance with legal provisions. These questions may be asked prior to the General Meeting by email to the address [email protected] or by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège. These questions must be received by the Company on 18 May 2020 at 17h00 (Belgian time) at the latest.
Further information relating to the abovementioned right and the modalities for exercising them are available on the Company's website (www.mithra.com).
Any shareholder who wished to vote for that meeting shall be represented by a proxy holder determined by the Company. Shareholders wishing to be represented must use the proxy form established by the board of directors. The proxy form may be obtained on the Company's website (www.mithra.com)or upon request at the Company's registered office, or by email to [email protected].
The original form signed on paper form must be received by the Company on 18 May 2020 at 24h00 (Belgian time) at the latest. This form may be communicated to the Company by mail marked for the attention of Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to [email protected]. Shareholders are invited to follow the instructions set out in the proxy form in order to be validly represented at the meeting.
Shareholders wishing to be represented must comply with the registration and confirmation procedure described above.
All documents concerning the general meeting that are required by law to be made available to shareholders as well as the text of the amended articles of association following the approval of the amendments proposed on the agenda may be consulted on the Company's website (www.mithra.com)as from 22 April 2020. As from the same date, shareholders have the right to consult these documents on business days and during normal office hours, at the Company's registered office and/or, upon display of their securities, obtain copies of these documents free of charge.
Requests for copies may also be made, free of charge, by mail (writing) marked for the attention Mithra Pharmaceuticals SA, Corporate Secretary, 5, rue Saint-Georges à 4000 Liège, or by email to [email protected].
********
Christophe Maréchal (IRO) : +32 495 55 14 78 - [email protected] Maud Vanderthommen (Press) : +32 473 58 61 04 – [email protected]
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Its three lead development candidates are built on Mithra's unique native estrogen platform, Estetrol (E4): Estelle®, a new era in oral contraception, PeriNesta®, the first complete oral treatment for perimenopause and Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 85 countries around the world, Mithra has an approximate headcount of 250 staff members and is headquartered in Liège, Belgium. www.mithra.com
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
News Alerts
Subscribe to our mailing list on investors.mithra.com to receive our press releases by email or follow us on our social media :
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.